States Eye Expanded Drug Price Review Boards as Costs Rise

In response to rising drug prices, some states have launched prescription drug review boards designed to make medicines more affordable. So far, the boards control prices mainly for states’ Medicaid and state employee plans, but some states are considering whether to set up panels that would also work to set upper payment limits for prescription drugs in commercial insurance.

A new report by professional services firm Manatt found that 17 states so far have implemented or introduced legislation for boards that exercise some influence on drug prices, primarily in the realm of plans controlled by state governments — state Medicaid plans and commercial plans in which the state government is the plan sponsor. The report found that six states — Maine, Maryland, Massachusetts, New Hampshire, New York and Ohio — have such boards in place.

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today